GlassScriptPhysician profile
Lauren D Fahey
NPI 1750614400
$5,205.46
in general payments reported to CMS, 2019-2025
25 companies · $511 in 2025
The $511 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,605 · 2022: $1,666 · 2023: $646 · 2024: $777 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,934.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,666.26 | 2021-2025 | |
| Abbvie INC. | $397.67 | 2021-2023 | |
| Ucb, INC. | $336.06 | 2021-2025 | Cimzia, Bimzelx |
| Lilly USA, LLC | $317.93 | 2021-2024 | Taltz |
| Incyte Corporation | $285.24 | 2021-2024 | Opzelura |
| Leo Pharma INC. | $205.31 | 2021-2025 | Anzupgo |
| Galderma Laboratories, L.P. | $180.58 | 2021-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $178.98 | 2021-2024 | Siliq |
| Regeneron Healthcare Solutions, INC. | $178.41 | 2022-2024 | Libtayo, Dupixent |
| Janssen Biotech, INC. | $170.19 | 2021-2024 | Tremfya |
| Janssen Scientific Affairs, LLC | $164.78 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $155.83 | 2022-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $140.69 | 2021-2024 | |
| Epi Health, LLC | $120.33 | 2022 | |
| Pfizer INC. | $117.26 | 2021-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $112.06 | 2021 | |
| Almirall LLC | $102.94 | 2022 | |
| Genzyme Corporation | $90.71 | 2021-2024 | |
| Organogenesis INC. | $72.87 | 2021-2024 | Puraply, Affinity |
| Mayne Pharma Commercial LLC | $63.86 | 2021-2025 | |
| Dermavant Sciences, INC. | $44.46 | 2023-2024 | Vtama |
| Amgen INC. | $37.13 | 2021 | |
| Biofrontera INC. | $32.86 | 2022-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Paratek Pharmaceuticals, INC. | $17.59 | 2022 | |
| Kerecis Limited | $15.46 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Fahey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.